Sinopia Biosciences Awarded Second NHLBI Phase II SBIR

Sinopia Biosciences received a second Phase II Small Business Innovation Research (SBIR) Grant from the National Heart, Lung, and Blood Institute (NHLBI) branch of the National Institutes of Health (NIH) to support research and commercialization of transfusion products. Titled "Improving the safety and efficacy of platelet transfusion through systems biology", the award for approximately $1.5 million will support the deployment of Sinopia's platform for platelet transfusion products. In Phase I, Sinopia’s systems biology platform discovered biochemical alterations in platelet metabolism over time through comprehensive metabolite profiling and computational analyses. This Phase II grant focuses on testing novel additives to combat the metabolic changes in order to better preserve cells for transfusion and potentially extend the shelf life of platelet products. The multi-center project will strengthen existing key collaborations with the San Diego Blood Bank and blood metabolomics experts at Omix Technologies.